会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 42. 发明授权
    • Slide switch assemblies
    • 滑动开关组件
    • US07022931B2
    • 2006-04-04
    • US11005302
    • 2004-12-07
    • Yuji ShimodaHiroshi Ochiai
    • Yuji ShimodaHiroshi Ochiai
    • H01H15/06
    • B60Q3/16B60Q3/82H01H15/04H01H15/06
    • A slide switch assembly comprises a housing and a slider having traveling contacts which define exposed contact faces. An accommodation section is formed in the housing to receive the slider and allow the slider to be moved slideably therein. A printed circuit board having fixed contact plates is attached to the printed circuit board. The printed circuit board is assembled with the housing such that the fixed contact plates are in opposition to the traveling contacts and adapted to make electrical contact with the traveling contacts in response to sliding movement of the slider. Preferably, the printed circuit board includes a printed conduction pattern, and the fixed contact plates include fixation bases adapted to be soldered to the conduction pattern and a bent contact portion extending therefrom. The accommodation section is most preferably defined by a partition wall having openings such that the contact portions of the fixed contact plates are positioned to be exposed through the openings.
    • 滑动开关组件包括壳体和具有限定暴露的接触面的行进触点的滑块。 在壳体中形成容纳部分以容纳滑块并允许滑块在其中可滑动地移动。 具有固定接触板的印刷电路板安装在印刷电路板上。 印刷电路板与壳体组装,使得固定接触板与行进触点相对,并且适于响应于滑块的​​滑动运动而与行进触点电接触。 优选地,印刷电路板包括印刷导电图案,并且固定接触板包括适于被焊接到导电图案的固定基座和从其延伸的弯曲接触部分。 容纳部最优选地由具有开口的分隔壁限定,使得固定接触板的接触部分定位成通过开口露出。
    • 48. 发明授权
    • Surface treatment apparatus
    • US5531830A
    • 1996-07-02
    • US354040
    • 1994-12-06
    • Kiyohiro IchinoseHirofumi HaraHiroshi Ochiai
    • Kiyohiro IchinoseHirofumi HaraHiroshi Ochiai
    • B65G49/04B66C1/12B66C1/16C25D13/22B05C3/09
    • B66C1/16B65G49/0459B66C1/12C25D13/22
    • A surface treatment apparatus having a treatment bath for immersing and treating a workpiece therein with the workpiece being put into and taken out of said treatment bath by the lifting and lowering thereof and with the workpiece being rotated about a horizontal axial line while in the bath. A jig is provided for holding the workpiece having a pair of suspending points at each end thereof in symmetrical relationship about a horizontal axial line. Ropes suspend the jig with each one connected to one of the suspending points at each end of said jig. In a first embodiment, a pair of hoisting apparatuses are provided with upper ends of the ropes connected to suspending points on one side at both ends of the jig being connected to one of the hoisting apparatuses and upper ends of the ropes connected to suspending points on the other side at both ends of the jig being connected to the other of the hoisting apparatuses. In a second embodiment, a pair of jig-rotating wheels are fixed on the same horizontal axial line at both ends of the jig. The ropes for suspending the jig are respectively wound around the jig-rotating wheels. A pair of hoisting apparatuses are provided with one end of each of the ropes being connected to one of the hoisting apparatuses and the other end of each of the ropes being connected to the other of the hoisting apparatuses. In a third embodiment four ropes are used, and in a fourth embodiment a pair of shaft extension portions are used instead of wheels.
    • 49. 发明授权
    • Compound having acidic group which may be protected, and use thereof
    • 具有可被保护的酸性基团的化合物及其用途
    • US08618122B2
    • 2013-12-31
    • US12301194
    • 2007-05-15
    • Kensuke KusumiMasaya KokuboHiroshi OchiaiShiro Shibayama
    • Kensuke KusumiMasaya KokuboHiroshi OchiaiShiro Shibayama
    • A61K31/44A61K31/415C07D215/00C07D233/00
    • C07D471/10
    • A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
    • 由通式(I)表示的化合物:其盐,其溶剂合物或其前药,其中所有符号如说明书中所定义。 本发明的化合物对CXCR4具有拮抗作用,因此可用作CXCR4介导的疾病的预防和/或治疗剂,例如炎性和免疫疾病(例如类风湿性关节炎,关节炎,全身性红斑狼疮,视网膜病变, 黄斑变性,肺纤维化,移植器官排斥反应等),过敏性疾病,感染(例如人类免疫缺陷病毒感染,获得性免疫缺陷综合征等),精神神经病,脑疾病,心血管疾病,代谢疾病,癌性疾病 例如癌症,癌症转移等)或再生治疗剂。
    • 50. 发明授权
    • Chemokine receptor antagonists and use thereof
    • 趋化因子受体拮抗剂及其用途
    • US08519124B2
    • 2013-08-27
    • US13415399
    • 2012-03-08
    • Masaya KokuboHiroshi OchiaiYoshikazu TakaokaShiro Shibayama
    • Masaya KokuboHiroshi OchiaiYoshikazu TakaokaShiro Shibayama
    • C07D221/20C07D265/14C07D401/14C07D403/12C07D403/14
    • C07D403/12C07D233/64C07D401/12C07D403/14C07D471/10C07D498/10
    • A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.
    • 由通式(I)表示的化合物:其盐,其溶剂化物或前药,其中所有符号如本说明书中所定义,具有对CXCR4的拮抗活性,因此可用作预防和/或治疗剂 CXCR4介导的疾病,例如炎症和免疫疾病(例如类风湿性关节炎,关节炎,全身性红斑狼疮,视网膜病变,黄斑变性,肺纤维化,移植器官排斥反应等),过敏性疾病,感染(例如人类免疫缺陷 病毒感染,获得性免疫缺陷综合征等),精神神经病,脑疾病,心脏/血管疾病(例如动脉硬化,心肌梗塞,心动过速,脑梗死,慢性动脉闭塞性疾病等),代谢疾病和癌性疾病 (例如,癌症,癌症转移等),癌性疾病或感染的预防和/或治疗剂, 或再生治疗剂。